Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia (Q36040720)

11 August 2017

1 reference

title

Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia (English)

1 reference

11 August 2017

1 reference

1 reference

Peter P Toth

1 reference

11 August 2017

Michael H Davidson

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

Expert Opinion on Pharmacotherapy

11 August 2017

1 reference

inferred from page(s)

published in

1 reference

11 August 2017

1 reference

11 August 2017

1 reference

11 August 2017

page(s)

131-139

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Evidence that triglycerides are an independent coronary heart disease risk factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Evidence-based guidelines for cardiovascular disease prevention in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

High-density lipoprotein and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Reverse cholesterol transport: high-density lipoprotein's magnificent mile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Therapeutic interventions targeted at the augmentation of reverse cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Inhibition of LOX-1 by statins may relate to upregulation of eNOS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Time-dependent effect of statins on platelet function in hypercholesterolaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

hsCRP and HDL effects of statins trial (CHEST): rapid effect of statin therapy on C-reactive protein and high-density lipoprotein levels A clinical investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

C-reactive protein and risk of cardiovascular disease: evidence and clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Simvastatin reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Mechanistic studies on metabolic interactions between gemfibrozil and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Sterol absorption by the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Hypolipidemic therapy and cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

The discovery of ezetimibe: a view from outside the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

RETRACTED: Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

Lifetime risk of developing coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.6.1.131

21 January 2018

Identifiers

DOI

10.1517/14656566.6.1.131

1 reference

11 August 2017

1 reference